National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis

Update: 2025-07-01

Description

In this podcast accompanying the July issue of DTB (https://dtb.bmj.com/content/63/7), David Phizackerley (DTB Editor) is joined by Syba Sunny (Clinical Editor). David and Syba discuss the editorial (https://dtb.bmj.com/content/63/7/98) which focuses on some key changes in the new national asthma guideline and the implications for patients and healthcare professionals. A DTB Select article (https://dtb.bmj.com/content/63/7/99) provides an overview of a double-blind randomised placebo-controlled trial that assessed whether bisoprolol reduced the number of exacerbations in people with COPD. The main article (https://dtb.bmj.com/content/63/7/103) is an overview of abaloparatide, which is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

The podcast begins with a discussion about ideas for new articles for DTB and the therapeutic areas currently under consideration. If you have a suggestion for an article that you would like DTB to cover, please email details to dtb@bmj.com.

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.

Comments

In Channel

Medicines - but at what cost, direct penicillin allergy challenge, and prescribing mistakes

2025-11-0320:12

Orphan drugs, allopurinol and CVD, mavacamten for obstructive hypertrophic cardiomyopathy

2025-10-0130:14

Antibiotic susceptibility reports, deprescribing, and heart failure drugs

2025-09-0517:53

AI and DTB, drug safety, tirzepatide, and lecanemab for Alzheimer's disease

2025-07-3138:47

National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis

2025-07-0122:52

Identifying VTE in early pregnancy, gabapentinoids and COPD, managing ADHD

2025-06-0339:30

The polypill revisited, cytisinicline for vaping cessation and a new co-host

2025-05-0919:28

Misuse of female empowerment to sell tests and treatments, triptan safety, use of ACEI or AIIRA in CKD

2025-04-0228:17

Paying the price, liver problems with fezolinetant, systemic anticancer treatments

2025-03-0331:57

Prioritising shared decision making, remission from type 2 diabetes, gefapixant for cough

2025-01-2709:08

PILs: all harms and no benefits, Irish College of GPs end pharma funding, Ryeqo for fibroids

2024-12-3029:00

When it comes to drugs, sex matters; menopausal HT and dementia; daridorexant for sleep

2024-11-2827:53

Supporting obesity treatment, major bleeds with anticoagulants and SSRIs, equity in COPD care

2024-10-3024:31

(Un)common sense in oncology, DOACs in device-detected AF, and hypertension in the elderly

2024-09-2519:49

Medicines optimisation measures, warfarin-tramadol interaction and icosapent ethyl

2024-09-0622:48

Psychotropic medicines in children, warfarin vs DOAC in old age, and fezolinetant in menopause

2024-07-2920:19

Propranolol and its risk in overdose and managing COPD exacerbations

2024-07-0117:19

Diagnostic imaging and shielding, sinusitis, antibiotics and coloured snot, ritlecitinib

2024-05-2923:05

Medicines and global warming, donanemab for AD, and cytisine for smoking cessation

2024-04-2526:02

Drug safety alerts, valproate safety (again) and a new contraceptive POP

2024-03-2631:09

00:00

National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis

#box-pro-ellipsis-176271404277042{-webkit-line-clamp:2;}National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis

National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis

BMJ Group

National asthma guidelines, bisoprolol for COPD and abaloparatide for osteoporosis